A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients - Test2 - elhamkhani - TriplyDB

A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients

A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients

http://www.wikidata.org/entity/Q35484320

about

Fever Interleukin-1 in the pathogenesis and treatment of inflammatory diseases Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory Therapies Immune interventions in stroke The Yin and Yang of innate immunity in stroke Rational modulation of the innate immune system for neuroprotection in ischemic stroke Neuroinflammatory basis of metabolic syndrome Neuroprotection for stroke: current status and future perspectives Targeting interleukin-1 in heart disease Neuroinflammation in overnutrition-induced diseases Genetic ablation of Pannexin1 protects retinal neurons from ischemic injury Emerging Roles for the Immune System in Traumatic Brain Injury Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke Does inflammation predispose to recurrent vascular events after recent transient ischaemic attack and minor stroke? The North West of England transient ischaemic attack and minor stroke (NORTHSTAR) study Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study Neuroinflammation and cerebrovascular disease in old age: a translational medicine perspective Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosis--A Pilot Study Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury IL1RN VNTR polymorphism in ischemic stroke: analysis in 3 populations.Polymorphisms of the IL1-receptor antagonist gene (IL1RN) are associated with multiple markers of systemic inflammation.Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production.Interleukin-1 primes human mesenchymal stem cells towards an anti-inflammatory and pro-trophic phenotype in vitro Vulnerability to stroke: implications of perinatal programming of the hypothalamic-pituitary-adrenal axis Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial.Molecular dialogs between the ischemic brain and the peripheral immune system: dualistic roles in injury and repair Plasma interleukin-1beta concentration is associated with stroke in sickle cell disease.Neurotherapeutic activity of the recombinant heat shock protein Hsp70 in a model of focal cerebral ischemia in rats.Translational pharmacokinetics: challenges of an emerging approach to drug development in stroke.Post-stroke infection: a role for IL-1ra?Stroke, IL-1ra, IL1RN, infection and outcome.The Immune Response to Acute Focal Cerebral Ischemia and Associated Post-stroke Immunodepression: A Focused Review.IL-1 blockade in autoinflammatory syndromes.The dual role of the neuroinflammatory response after ischemic stroke: modulatory effects of hypothermia.Interleukin 1 receptor signaling regulates DUBA expression and facilitates Toll-like receptor 9-driven antiinflammatory cytokine production.Acute NADPH oxidase activation potentiates cerebrovascular permeability response to bradykinin in ischemia-reperfusion.Neurogenesis and inflammation after ischemic stroke: what is known and where we go from here.Serum cytokine and glucose levels as predictors of poststroke fatigue in acute ischemic stroke patients Neuroinflammation and neuroimmune dysregulation after acute hypoxic-ischemic injury of developing brain The role of microglia and myeloid immune cells in acute cerebral ischemia.

P2860

Q24603393-1934EA7A-79DC-413D-BB07-96AD3FFA9017 Q24606766-593CDDEE-673D-457A-9D31-2A5A0DDE22F3 Q26746659-9B1BB889-B4EF-41B5-968F-2F6C6D525BA2 Q26786973-E32474A0-B0D7-495B-AB35-DB1703E6D35B Q26797993-7A79B7B0-2BF9-4DCA-9537-8BF3DA7471C0 Q26822268-B0EE5E9B-BB36-4937-AC87-EF7DD97E3661 Q26851831-1F31D971-FE99-4F0E-8BF8-084344972766 Q26852584-5AF29F87-5BF1-46EA-BEBC-54F29EDAF9F1 Q26853031-4871E9AC-9C93-46E0-8828-2A18EBFB6796 Q27009347-7CC003A5-EAB3-4320-8B1E-B175910FF56A Q27013624-0830E7BA-AB1F-4076-B07C-A44F045BB283 Q27308767-2D8090D0-DAC9-485D-800A-0CA800C4105C Q28071271-0A74AF6E-325B-42D3-B437-127277779BF3 Q28078744-CDCCAE6E-7ED7-43E2-94A4-02B704EB7803 Q28237202-09CC4A6C-1A15-49C5-9F7A-23A5CCFB33BF Q28287860-9203AFEB-2D80-4CFA-94D4-F01BE553CD4B Q28393202-FE7405FA-B86B-40C6-ADC7-743DEFF7F8DD Q28550089-A39CE882-7164-41E1-A6BC-36FF167F1A14 Q28582906-E6066269-6F6B-4070-809E-E53C9D7E2A76 Q30440385-D0BB722B-15DD-4A41-90B6-60641FAA52E8 Q30490407-CE3F0A17-215B-459A-909F-0D3889BD80BB Q33276036-19ECF49B-129E-480A-A1E0-A4D93F5A78FA Q33568772-64604FA3-24E6-4FA0-A848-C917D9468054 Q33575275-4E58F783-6B14-450E-88F1-1C38F0CD4E98 Q33581165-35E1F1AF-7714-4E49-AAEE-7E79A9D29CDA Q33583258-0ECDEDC3-0A3B-4E90-9C83-4C7EB43FB582 Q33598716-0F4775B2-6FDE-4F33-A2AF-045847368499 Q33709375-49E39B37-440D-4B61-84CB-7A0AE2477D4A Q33882182-52829173-B4A8-4D81-A902-D0C411268900 Q33897235-932D3E75-8472-4183-BE31-DFA8C2DFBBF1 Q34164095-EDBA2DEA-5F2E-4360-8073-84E29E6FA90A Q34237954-854FFD70-6FFA-4CE2-A499-1DC8C597B70D Q34262561-5FC2E401-A5A0-4D2D-B20F-13737DF61144 Q34335614-BB7CCAEA-C8ED-4FA7-8F8A-07570E23BE89 Q34420855-5FAE91F5-F76E-4DB8-8112-60DC6D562439 Q34571046-A5D6DE0A-3A0E-49A8-A484-52C362804045 Q34727139-BD7A38FF-0407-4138-8CF0-EC7B3DA969E3 Q34729401-3725367B-090B-44D8-9D08-AC06629B6580 Q34954213-8A11AE29-F85E-433D-BFEF-C8CB45630B93 Q34954361-78AC857C-CC55-46A4-8398-353D09A9D5EB

P2860

A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients

http://www.wikidata.org/entity/Q35484320

description

2005 nî lūn-bûn

@nan

2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients

@ast

A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients

@en

type

label

A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients

@ast

A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients

@en

prefLabel

A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients

@ast

A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients

@en

P1433

Q35484320-CE30E58E-5355-47A5-9229-263D65BCF23B

P1476

Q35484320-7E9A71F9-223C-4271-A301-70E685E8CC59

P2093

Q35484320-37CCE740-9E0E-4728-9974-27F962B9AEA9

Q35484320-513F8E53-0E0A-4C13-80D2-D7FE7BE802BC

Q35484320-795B8616-2C6F-4AE1-92B0-1B6677C482A6

Q35484320-A789DFB1-1CBE-4DEB-AD99-3CA9F3E2F225

Q35484320-ABC1E871-3EE2-430E-8504-CAC8A721D7FA

Q35484320-CB6E8069-7B7F-4BE3-8972-6DEBE5C82823

Q35484320-D258E840-FAC8-4E9D-9683-F453957E84E0

P2860

Q35484320-055F4AF6-E29E-4398-9221-80272A0366CB

Q35484320-081A952E-EACD-4636-8676-AD984D62FAD1

Q35484320-1765130E-DAC7-467F-9912-052EBD8A5D8A

Q35484320-1F0D1461-EB2D-4421-81AB-C6AC18F1C33D

Q35484320-222E58F7-A291-400D-A751-C34F53CD2422

Q35484320-2F8222D3-0E87-419A-A53E-CA29A22E3BF1

Q35484320-3045E7D8-0721-4ACF-A98C-AB22977A19B3

Q35484320-37B3A4BF-C696-4690-A940-34AFE29B3D5D

Q35484320-47386525-BA19-43EB-B422-E2266B006443

Q35484320-7EA60AB8-2884-4F9D-9BA0-26B4BD5B36A9

P304

Q35484320-56280C3B-D700-4C21-95E1-9C479722CEEE

P31

Q35484320-D59C2465-88B1-45D0-B2F7-614D5FBE5CF4

P356

Q35484320-6FAC6FFC-3C92-4199-B3F7-BEED84DBC5FE

P407

Q35484320-77D9FD22-825B-429A-943E-9C36763548F1

P433

Q35484320-1FACE148-4DF1-45C0-B8CB-94E989EB69AA

P478

Q35484320-FD88F31B-A932-46F3-8AAA-20F5D43735D8

P50

Q35484320-8B7DDF95-9243-4243-9EE9-5638FC69FBE9

P577

Q35484320-981F27DC-6FDE-46AD-BB95-7CBABDE45A09

P5875

Q35484320-E184A664-1D2B-4A9E-8EB7-5C4141F61D6F

P698

Q35484320-D877A3C9-8C35-48D1-863F-DDC56E32D95D

P932

Q35484320-5F90AEDF-CA14-4007-8531-5C6616DD9B06

P356

JNNP.2004.054882

P1433

Journal of Neurology, Neurosurgery and Psychiatry

P1476

A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients

@en

P2093

A Vail

http://www.w3.org/2001/XMLSchema#string

Acute Stroke Investigators

http://www.w3.org/2001/XMLSchema#string

C J Smith

http://www.w3.org/2001/XMLSchema#string

H C A Emsley

http://www.w3.org/2001/XMLSchema#string

N J Rothwell

http://www.w3.org/2001/XMLSchema#string

R F Georgiou

http://www.w3.org/2001/XMLSchema#string

S J Hopkins

http://www.w3.org/2001/XMLSchema#string

P2860

Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome

The balance between IL-1 and IL-1Ra in disease

FUNCTIONAL EVALUATION: THE BARTHEL INDEX

Classification and natural history of clinically identifiable subtypes of cerebral infarction

Does the National Institutes of Health Stroke Scale favor left hemisphere strokes? NINDS t-PA Stroke Study Group.

The medical dictionary for regulatory activities (MedDRA).

Potential mechanisms of interleukin-1 involvement in cerebral ischaemia.

Ischemic penumbra: evidence from functional imaging in man.

Interobserver agreement for the assessment of handicap in stroke patients.

Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential.

P304

1366-1372

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JNNP.2004.054882

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P50

Pippa J Tyrrell

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7593840

http://www.w3.org/2001/XMLSchema#string

P698

16170078

http://www.w3.org/2001/XMLSchema#string

P932

1739363

http://www.w3.org/2001/XMLSchema#string